Vor Biopharma Inc
VORHealthcare|Biotechnology|USA
$19.14
-0.61 (-3.09%)
Earnings Power
$10.66
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07404865 Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease | Primary Sjogren's Disease | P3 | Recruiting | 250 | RCT, Double-blind | Telitacicept, Placebo |
| NCT06456580 A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | Generalized Myasthenia Gravis | P3 | Recruiting | 180 | RCT, Double-blind | Telitacicept, Placebo |
| NCT06456567 A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) | Systemic Lupus Erythematosus | P3 | Withdrawn | — | RCT, Double-blind | Telitacicept, Placebo |
| NCT05306574 A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) | Systemic Lupus Erythematosus | P3 | Terminated | 91 | RCT, Double-blind | Telitacicept, Placebo |
| NCT05984199 Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | Leukemia, Myeloid, Acute | P1P2 | Terminated | 38 | Open-label | VCAR33 |
| NCT04849910 Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | P1P2 | Terminated | 67 | RCT, Open-label | VOR33, Mylotarg |
| NCT05309733 A Long-term Follow-up Study of Patients Who Received VOR33 | Leukemia, Myeloid, Acute | Terminated | 10 | — | — |